Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CYP2D6' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 558 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Walton, R; Johnstone, E; Munafo, M; Neville, M; Griffiths, S
      Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy

      TRENDS IN MOLECULAR MEDICINE
    2. Bendriss, EK; Markoglou, N; Wainer, IW
      High-performance liquid chromatography assay for simultaneous determination of dextromethorphan and its main metabolites in urine and in microsomal preparations

      JOURNAL OF CHROMATOGRAPHY B
    3. Ingelman-Sundberg, M
      Genetic susceptibility to adverse effects of drugs and environmental toxicants - The role of the CYP family of enzymes

      MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
    4. Povey, AC; Hall, CN; Badawi, AF; Cooper, DP; Guppy, MJ; Jackson, PE; O'Connor, PJ; Margison, GP
      Host determinants of DNA alkylation and DNA repair activity in human colorectal tissue: O-6-methylguanine levels are associated with GSTT1 genotype and O-6-alkylguanine-DNA alkyltransferase activity with CYP2D6 genotype

      MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
    5. Furuno, T; Kawanishi, C; Iseki, E; Onishi, H; Sugiyama, N; Suzuki, K; Kosaka, K
      No evidence of an association between CYP2D6 polymorphisms among Japanese and dementia with Lewy bodies

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    6. Wilson, JF; Weale, ME; Smith, AC; Gratrix, F; Fletcher, B; Thomas, MG; Bradman, N; Goldstein, DB
      Population genetic structure of variable drug response

      NATURE GENETICS
    7. Cox, DG; Boillot, C; Canzian, F
      Data mining: Efficiency of using sequence databases for polymorphism discovery

      HUMAN MUTATION
    8. Ekins, S; Wrighton, SA
      Application of in silico approaches to predicting drug-drug interactions

      JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
    9. Smith, G; Sachse, C
      A role for CYP2D6 in nicotine metabolism? Target article on nicotine-addiction

      PSYCOLOQUY
    10. Vakhitova, YV; Soultanaeva, ZM; Viktorova, TV; Bikmaeva, AR; Khusnutdinova, EK
      Polymorphism of human glutatione S-transferase gene in the populations of the Volga-Ural region

      RUSSIAN JOURNAL OF GENETICS
    11. Tsuzuki, D; Takemi, C; Yamamoto, S; Tamagake, K; Imaoka, S; Funae, Y; Kataoka, H; Shinoda, S; Narimatsu, S
      Functional evaluation of cytochrome P450 2D6 with Gly(42)Arg substitution expressed in Saccharomyces cerevisiae

      PHARMACOGENETICS
    12. Allorge, D; Harlow, J; Boulet, O; Hayhurst, GP; Chowdry, J; Roth, E; Crewe, K; Lo-Guidice, JM; Lhermitte, M; Broly, F; Tucker, GT; Ellis, SW
      In-vitro analysis of the contribution of CYP2D6.35 to ultrarapid metabolism

      PHARMACOGENETICS
    13. Ramamoorthy, Y; Tyndale, RF; Sellers, EM
      Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates

      PHARMACOGENETICS
    14. Wan, YJY; Poland, RE; Han, G; Konishi, T; Zheng, YP; Berman, N; Lin, KM
      Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California

      PHARMACOGENETICS
    15. Wennerholm, A; Johansson, I; Hidestrand, M; Bertilsson, L; Gustafsson, LL; Ingelman-Sundberg, M
      Characterization of the CYP2D6*29 allele commonly present in a blade Tanzanian population causing reduced catalytic activity

      PHARMACOGENETICS
    16. Streetman, DS; Kashuba, ADM; Bertino, JS; Kulawy, R; Rocci, ML; Nafziger, AN
      Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping

      PHARMACOGENETICS
    17. Shimada, T; Tsumura, F; Yamazaki, H; Guengerich, FP; Inoue, K
      Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6

      PHARMACOGENETICS
    18. Lovlie, R; Daly, AK; Matre, GE; Molven, A; Steen, VM
      Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?

      PHARMACOGENETICS
    19. Griese, EU; Ilett, KF; Kitteringham, NR; Eichelbaum, M; Powell, H; Spargo, RM; LeSouef, PN; Musk, AW; Minchin, RF
      Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia

      PHARMACOGENETICS
    20. Ingelman-Sundberg, M
      Pharmaco genetics: an opportunity for a safer and more efficient pharmacotherapy

      JOURNAL OF INTERNAL MEDICINE
    21. Bechtel, YC; Lelouet, H; Hrusovsky, S; Brientini, MP; Mantion, G; Paintaud, G; Miguet, JP; Bechtel, PR
      Caffeine metabolism before and after liver transplantation

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    22. Davis, MP; Homsi, J
      The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine

      SUPPORTIVE CARE IN CANCER
    23. Catalano, M
      Functionally gene-linked polymorphic regions and genetically controlled neurotransmitters metabolism

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    24. Narimatsu, S; Arai, T; Masubuchi, Y; Horie, T; Hosokawa, M; Ueno, K; Kataoka, H; Yamamoto, S; Ishikawa, T; Cho, AK
      Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    25. Mihara, K; Kondo, T; Suzuki, A; Yasui-Furukori, N; Ono, S; Otani, K; Kaneko, S
      Effects of genetic polymorphism of CYP1A2 inducibility on the steady-stateplasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients

      PHARMACOLOGY & TOXICOLOGY
    26. Kitazawa, E; Igarashi, T; Kawaguchi, N; Matsushima, H; Kawashima, Y; Hankins, RW; Miyakawa, H
      Differences in anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and -positive patients

      JOURNAL OF AUTOIMMUNITY
    27. Murphy, GM; Pollock, BG; Kirshner, MA; Pascoe, N; Cheuk, W; Mulsant, BH; Reynolds, CF
      CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression

      NEUROPSYCHOPHARMACOLOGY
    28. Coecke, S; Bogni, A; Langezaal, I; Worth, A; Hartung, T; Monshouwer, M
      The use of genetically engineered cells for assessing CYP2D6-related polymorphic effects

      TOXICOLOGY IN VITRO
    29. Harhangi, BS; Oostra, BA; Heutink, P; van Duijn, CM; Hofman, A; Breteler, MMB
      CYP2D6 polymorphism in Parkinson's disease: The Rotterdam study

      MOVEMENT DISORDERS
    30. Rodriguez, JB
      Pharmacogenetics in clinical pharmacology: Present and future

      METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
    31. Slanar, O; Perlik, F; Jirasek, V
      Phenotype of cytochrome P450CYP2D6 in patients with familial adenomatous polyposis

      METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
    32. Ingelman-Sundberg, M
      Genetic variability in susceptibility and response to toxicants

      TOXICOLOGY LETTERS
    33. Ishii, M; Xu, BQ; Ding, LR; Fischer, NE; Inaba, T
      Interaction of plasma proteins with cytochromes P450 mediated metabolic reactions: inhibition by human serum albumin and alpha-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat

      TOXICOLOGY LETTERS
    34. Xie, HG; Kim, RB; Wood, AJJ; Stein, CM
      Molecular basis of ethnic differences in drug disposition and response

      ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
    35. Kvist, EE; Al-Shurbaji, A; Dahl, ML; Nordin, C; Alvan, G; Stahle, L
      Quantitative pharmacogenetics of nortriptyline - A novel approach

      CLINICAL PHARMACOKINETICS
    36. Roh, HK; Chung, JY; Oh, DY; Park, CS; Svensson, JO; Dahl, ML; Bertilsson, L
      Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    37. Webb, JA; Rostami-Hodjegan, A; Abdul-Manap, R; Hofmann, U; Mikus, G; Kamali, F
      Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    38. Senda, C; Yamaura, Y; Kobayashi, K; Fujii, H; Minami, H; Sasaki, Y; Igarashi, T; Chiba, K
      Influence of the CYP2D6*10 allele on the metabolism of mexiletine by humanliver microsomes

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    39. Matsumoto, S; Yamazoe, Y
      Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    40. Hagg, S; Spigset, O; Dahlqvist, R
      Influence of gender and oral contraceptives on CYP2D6 and CY2ZC19 activityin healthy volunteers

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    41. Shin, JG; Kane, K; Flockhart, DA
      Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    42. Iwahashi, K; Anemo, K; Nakamura, K; Fukunishi, I; Igarashi, K
      Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with, drug-induced parkinsonism

      NEUROPSYCHOBIOLOGY
    43. Liao, DL; Yeh, YC; Chen, HM; Chen, H; Hong, CJ; Tsai, SJ
      Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

      NEUROPSYCHOBIOLOGY
    44. Eap, CB; Bondolfi, G; Zullino, D; Savary-Cosendai, L; Powell-Golay, K; Kosel, M; Baumann, P
      Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    45. Eap, CB; Broly, F; Mino, A; Hammig, R; Deglon, JJ; Uehlinger, C; Meili, D; Chevalley, AF; Bertschy, G; Zullino, D; Kosel, M; Preisig, M; Baumann, P
      Cytochrome P450 2D6 genotype and methadone steady-state concentrations

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    46. Shad, MU; Marsh, C; Preskorn, SH
      The economic consequences of a drug-drug interaction

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    47. Teh, LK; Ismail, R; Yusoff, R; Hussein, A; Isa, MN; Rahman, ARA
      Heterogeneity of the CYP2D6 gene among Malays in Malaysia

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    48. Hayhurst, GP; Harlow, J; Chowdry, J; Gross, E; Hilton, E; Lennard, MS; Tucker, GT; Ellis, SW
      Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6

      BIOCHEMICAL JOURNAL
    49. Lam, LCW; Garcia-Barcelo, MM; Ungvari, GS; Tang, WK; Lam, VKL; Kwong, SL; Lau, BST; Kwong, PPK; Waye, MMY; Chiu, HFK
      Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients

      PHARMACOPSYCHIATRY
    50. Iorio, R; Giannattasio, A; Vespere, G; Vegnente, A
      LKM1 antibody and interferon therapy in children with chronic hepatitis C

      JOURNAL OF HEPATOLOGY
    51. Llerena, A; Berecz, R; de la Rubia, A; Fernandez-Salguero, P; Dorado, P
      Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes

      THERAPEUTIC DRUG MONITORING
    52. Carlsson, B; Olsson, G; Reis, M; Walinder, J; Nordin, C; Lundmark, J; Scordo, MG; Dahl, ML; Bengtsson, F; Ahlner, J
      Enantioselective analysis of citalopram and metabolites in adolescents

      THERAPEUTIC DRUG MONITORING
    53. Suzuki, Y; Someya, T; Shimoda, K; Hirokane, G; Morita, S; Yokono, A; Inoue, Y; Takahashi, S
      Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol

      THERAPEUTIC DRUG MONITORING
    54. Spina, E; Avenoso, A; Facciola, G; Scordo, MG; Ancione, M; Madia, A
      Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine

      THERAPEUTIC DRUG MONITORING
    55. Schulze, TG; Schumacher, J; Muller, DJ; Krauss, H; Alfter, D; Maroldt, A; Ahle, G; Maroldt, AO; Fernandez, ANY; Weber, T; Held, T; Propping, P; Maier, W; Nothen, MM; Rietschel, M
      Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and Tardive dyskinesia in schizophrenia

      AMERICAN JOURNAL OF MEDICAL GENETICS
    56. Kraner, JC; McCoy, DJ; Evans, MA; Evans, LE; Sweeney, BJ
      Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA)

      JOURNAL OF ANALYTICAL TOXICOLOGY
    57. Ladona, MG; Izquierdo-Martinez, M; de la Paz, MP; de la Torre, R; Ampurdanes, C; Segura, J; Sanz, EJ
      Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome

      ENVIRONMENTAL HEALTH PERSPECTIVES
    58. Hendershot, PE; Antal, EJ; Welshman, IR; Batts, DH; Hopkins, NK
      Linezolid: Pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorphanHBr

      JOURNAL OF CLINICAL PHARMACOLOGY
    59. Nomeir, AA; Ruegg, C; Shoemaker, M; Favreau, LV; Palamanda, JR; Silber, P; Lin, CC
      Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates

      DRUG METABOLISM AND DISPOSITION
    60. Alvan, G; Bertilsson, L; Dahl, ML; Ingelman-Sundberg, M; Sjoqvist, F
      Moving toward genetic profiling in patient care: The scope and rationale of pharmacogenetic/ecogenetic investigation

      DRUG METABOLISM AND DISPOSITION
    61. Dierks, EA; Stams, KR; Lim, HK; Cornelius, G; Zhang, HL; Ball, SE
      A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry

      DRUG METABOLISM AND DISPOSITION
    62. Nebert, DW; Roe, AL
      Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer

      SCIENCE OF THE TOTAL ENVIRONMENT
    63. Ismail, R; Teh, LK
      Genetic polymorphism of CYP2D6: Malaysian Indians have the highest frequency for CYP2D6*4 in Asia

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    64. Lohmann, PL; Rao, ML; Ludwig, M; Griese, EU; Zanger, UM; Morike, K; Maier, W; Bagli, M
      Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    65. Bergmann, TK; Bathum, L; Brosen, K
      Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    66. Tamminga, WJ; Wemer, J; Oosterhuis, B; Brakenhoff, JPG; Gerrits, MGF; de Zeeuw, RA; de Leij, LFMH; Jonkman, JHG
      An optimized methodology for combined phenotyping and genotyping on CYP2D6and CYP2C19

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    67. Abraham, BK; Adithan, C; Mohanasundaram, J; Shashindran, CH; Koumaravelou, K; Asad, M
      Genetic polymorphism of CYP2D6 in Tamil population

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    68. Agundez, JAG; Gallardo, L; Ledesma, MC; Lozano, L; Rodriguez-Lescure, A; Pontes, JC; Iglesias-Moreno, MC; Poch, J; Ladero, JM; Benitez, J
      Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients

      ONCOLOGY
    69. Ring, BJ; Eckstein, JA; Gillespie, JS; Binkley, SN; Vandenbranden, M; Wrighton, SA
      Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    70. Laine, K; Tybring, G; Hartter, S; Andersson, K; Svensson, JO; Widen, J; Bertilsson, L
      Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    71. Kusumoto, M; Ueno, K; Oda, A; Takeda, K; Mashimo, K; Takaya, K; Fujimura, Y; Nishihori, T; Tanaka, K
      Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    72. Claassen, JD; Pascoe, N; Schatzberg, AF; Murphy, GM
      Rapid detection of the C-1496G polymorphism in the CYP2D6*2 allele

      CLINICAL CHEMISTRY
    73. Schur, BC; Bjerke, J; Nuwayhid, N; Wong, SH
      Genotyping of cytochrome P450 2D6*3 and*4 mutations using conventional PCR

      CLINICA CHIMICA ACTA
    74. Steimer, W; Muller, B; Leucht, S; Kissling, W
      Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy

      CLINICA CHIMICA ACTA
    75. Zimova, G; Chladek, J; Martinkova, J; Beranek, M
      HPLC determination of dextromethorphan and its metabolites in plasma

      CHEMICKE LISTY
    76. Williams, DG; Hatch, DJ; Howard, RF
      Codeine phosphate in paediatric medicine

      BRITISH JOURNAL OF ANAESTHESIA
    77. Miller, GP; Hanna, IH; Nishimura, Y; Guengerich, FP
      Oxidation of phenethylamine derivatives by cytochrome P450 2D6: The issue of substrate protonation in binding and catalysis

      BIOCHEMISTRY
    78. Taioli, E; Mari, D; Franceschi, C; Bonafe, M; Monti, D; Bertolini, S; Marinelli, D; Garte, S
      Polymorphisms of drug-metabolizing enzymes in healthy nonagenarians and centenarians: Difference at GSTT1 locus

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    79. Deeni, YY; Paine, MJI; Ayrton, AD; Clarke, SE; Chenery, R; Wolf, CR
      Expression, purification, and biochemical characterization of a human cytochrome P450CYP2D6-NADPH cytochrome P450 reductase fusion protein

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    80. Hanna, IH; Kim, MS; Guengerich, FP
      Heterologous expression of cytochrome P450 2D6 mutants, electron transfer,and catalysis of bufuralol hydroxylation: The role of aspartate 301 in structural integrity

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    81. Nakamura, K; Hanna, IH; Cai, HL; Nishimura, Y; Williams, KM; Guengerich, FP
      Coumarin substrates for cytochrome P450 2D6 fluorescence assays

      ANALYTICAL BIOCHEMISTRY
    82. Geisler, SA; Olshan, AF
      GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: A Mini-HuGE review

      AMERICAN JOURNAL OF EPIDEMIOLOGY
    83. Kirchheiner, J; Brosen, K; Dahl, ML; Gram, LF; Kasper, S; Roots, I; Sjoqvist, F; Spina, E; Brockmoller, J
      CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

      ACTA PSYCHIATRICA SCANDINAVICA
    84. Zhou, HH; Liu, ZO
      Ethnic differences in drug metabolism

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    85. Topic, E; Stefanovic, M; Ivanisevic, AM; Blazinic, F; Culav, J; Skocilic, Z
      CYP2D6 genotyping in patients on psychoactive drug therapy

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    86. Stefanovic, M; Topic, E; Ivanisevic, AM; Relja, M; Korsic, M
      Genotyping of CYP2D6 in Parkinson's disease

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    87. Cerqueira, PM; Mateus, FH; Cesarino, EJ; Bonato, PS; Lanchote, VL
      Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotyped as extensive metabolizers

      JOURNAL OF CHROMATOGRAPHY B
    88. Hofmann, U; Pecia, M; Heinkele, G; Dilger, K; Kroemer, HK; Eichelbaum, M
      Determination of propafenone and its phase I and phase II metabolites in plasma and urine by high-performance liquid chromatography-electrospray ionization mass spectrometry

      JOURNAL OF CHROMATOGRAPHY B
    89. Basile, VS; Ozdemir, V; Masellis, M; Walker, ML; Heltzer, HY; Lieberman, JA; Potkin, SG; Alva, G; Kalow, W; Macciardi, FM; Kennedy, JL
      A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia

      MOLECULAR PSYCHIATRY
    90. Schlienger, RG; Klink, MH; Eggenberger, C; Drewe, J
      Seizures associated with therapeutic doses of venlafaxine and trimipramine

      ANNALS OF PHARMACOTHERAPY
    91. Roberts, R; Sullivan, P; Joyce, P; Kennedy, MA
      Rapid and comprehensive determination of cytochrome P450CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction

      HUMAN MUTATION
    92. Flockhart, DA; Oesterheld, JR
      Cytochrome P450-mediated drug interactions

      CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA
    93. Davies, SM; Robison, LL; Buckley, JD; Radloff, GA; Ross, JA; Parentesis, JP
      Glutathione S-transferase polymorphisms in children with myeloid leukemia:A children's cancer group study

      CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
    94. Clark, D; Morgan, A; Hananeia, L; Coulter, D; Olds, R
      Drug metabolism genotypes and their association with adverse drug reactions in selected populations: a pilot study of methodology

      PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
    95. Wu, D; Wang, XB; Chen, DF; Niu, TH; Ni, JT; Liu, X; Xu, XP
      Metabolic gene polymorphisms and risk of dysmenorrhea

      EPIDEMIOLOGY
    96. Takeshita, M; Miura, M; Ohkubo, T; Sugawara, K
      Asymmetric redox reactions in human liver stereoselective oxidation of optically active dihydrohaloperidols, dihydrobromoperidols and stereospecific reduction of haloperidol and bromoperidol

      ENANTIOMER
    97. Raimundo, S; Fischer, R; Eichelbaum, M; Griese, EU; Schwab, M; Zanger, UM
      Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6

      PHARMACOGENETICS
    98. Murphy, MP; Beaman, ME; Clark, LS; Cayouette, M; Benson, L; Morris, DM; Polli, JW
      Prospective GYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial

      PHARMACOGENETICS
    99. Haritos, VS; Ghabrial, H; Ahokas, JT; Ching, MS
      Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin

      PHARMACOGENETICS
    100. Roddam, PL; Rollinson, S; Kane, E; Roman, E; Moorman, A; Cartwright, R; Morgan, GJ
      Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia

      PHARMACOGENETICS


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/12/19 alle ore 14:55:42